$803 Million is the total value of Sofinnova Investments, Inc.'s 137 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NCNA | Buy | Nucana Biomed Ltdadr | $32,867,000 | +97.8% | 2,266,666 | +240.0% | 4.09% | +176.4% |
| ACRS | Buy | Aclaris Therapeutics | $14,127,000 | -36.8% | 1,911,573 | +24.2% | 1.76% | -11.7% |
| GILD | New | Gilead Sciences Inc | $13,343,000 | – | 213,331 | +100.0% | 1.66% | – |
| AZN | Buy | AstraZeneca PLCadr | $12,015,000 | +26.2% | 316,328 | +31.5% | 1.50% | +76.3% |
| INCY | New | Incyte Corp | $11,987,000 | – | 188,497 | +100.0% | 1.49% | – |
| BMRN | New | Biomarin Pharmaceutical Inc | $11,968,000 | – | 140,542 | +100.0% | 1.49% | – |
| HRTX | Buy | Heron Therapeutics Inc | $9,331,000 | -0.3% | 359,713 | +21.7% | 1.16% | +39.3% |
| RETA | New | Reata Pharmaceuticals Inc | $8,863,000 | – | 157,984 | +100.0% | 1.10% | – |
| Buy | MorphoSys AG | $8,217,000 | +156.1% | 80,536 | +168.5% | 1.02% | +258.0% | |
| RIGL | Buy | Rigel Pharmaceuticals Inc | $7,778,000 | -25.7% | 3,382,174 | +3.7% | 0.97% | +3.9% |
| XNCR | New | Xencor Inc | $7,221,000 | – | 199,682 | +100.0% | 0.90% | – |
| FOLD | Buy | Amicus Therapeutics Inc | $6,462,000 | +19.8% | 674,636 | +51.3% | 0.80% | +67.4% |
| SVRA | Buy | Savara Inc | $5,711,000 | -26.7% | 754,372 | +8.0% | 0.71% | +2.3% |
| DCPH | New | Deciphera Pharmaceuticals Inc | $5,572,000 | – | 265,475 | +100.0% | 0.69% | – |
| ICPT | New | Intercept Pharmaceuticals Inc | $5,491,000 | – | 54,472 | +100.0% | 0.68% | – |
| SRPT | Buy | Sarepta Therapeutics Inc | $5,337,000 | +10.5% | 48,894 | +63.4% | 0.66% | +54.3% |
| CLVS | New | Clovis Oncology Inc | $5,168,000 | – | 287,769 | +100.0% | 0.64% | – |
| NBIX | New | Neurocrine Biosciences Inc | $4,393,000 | – | 61,500 | +100.0% | 0.55% | – |
| MGNX | New | MacroGenics Inc | $4,228,000 | – | 332,921 | +100.0% | 0.53% | – |
| DERM | Buy | Dermira Inc | $3,899,000 | -27.8% | 542,224 | +9.5% | 0.49% | +1.0% |
| FGEN | New | FibroGen Inc | $3,702,000 | – | 80,000 | +100.0% | 0.46% | – |
| ORTX | New | Orchard Therapeutics PLCadr | $3,502,000 | – | 222,618 | +100.0% | 0.44% | – |
| EPZM | Buy | Epizyme Inc | $3,472,000 | +12.5% | 563,655 | +93.5% | 0.43% | +57.5% |
| FOMX | Buy | Foamix Pharmaceuticals Ltd | $2,987,000 | -22.1% | 832,293 | +24.5% | 0.37% | +8.8% |
| FATE | Buy | Fate Therapeutics Inc | $2,948,000 | +72.5% | 229,813 | +119.1% | 0.37% | +141.4% |
| FPRX | New | Five Prime Therapeutics Inc | $2,933,000 | – | 315,344 | +100.0% | 0.36% | – |
| GWPH | New | GW Pharmaceuticals PLCadr | $2,922,000 | – | 30,000 | +100.0% | 0.36% | – |
| KALA | Buy | Kala Pharmaceuticals Inc | $2,178,000 | +130.7% | 445,516 | +365.8% | 0.27% | +222.6% |
| IMGN | New | ImmunoGen Inc | $2,146,000 | – | 447,075 | +100.0% | 0.27% | – |
| OSMT | New | Osmotica Pharmaceuticals PLC | $1,961,000 | – | 253,089 | +100.0% | 0.24% | – |
| OTIC | Buy | Otonomy Inc | $1,894,000 | -30.3% | 1,023,865 | +3.7% | 0.24% | -2.5% |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $1,558,000 | +11.4% | 350,110 | +102.2% | 0.19% | +55.2% |
| CNAT | Buy | Conatus Pharmaceuticals Inc | $1,104,000 | -64.7% | 638,197 | +18.4% | 0.14% | -50.5% |
| PCRX | New | Pacira Pharmaceuticals Inc | $731,000 | – | 16,994 | +100.0% | 0.09% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2019-02-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.